- Home
- TROO vs AVIR Comparison
TROO vs AVIR Comparison
Compare TROO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TROO | AVIR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.1M | 429.1M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TROO | AVIR |
|---|---|---|
| Price | $2.29 | $5.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 358.0K | 213.1K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $2.78 |
| 52 Week High | $5.28 | $6.45 |
Technical Indicators
Market Signals| Indicator | TROO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 47.32 |
| Support Level | $2.13 | $5.03 |
| Resistance Level | $2.32 | $5.79 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 82.26 | 14.10 |
Price Performance
Historical ComparisonAbout TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.